Voyager Therapeutics Plunges as Board Members Leave
Voyager Therapeutics (VYGR) takes a 28% dive on Thursday following the news that two its board members had requested not to be nominated for re-election in the upcoming annual shareholder meeting. The reasoning provided, was that the duo needed to cut work commitments.
The two board members confirmed that “such request was not based upon any disagreement with the Board or with the management on any matter relating to the Company’s operations, policies or practices,” but that did not prevent the dive in share price.
VYGR is housed in the Gene Therapy PRISM Index, which tumbled 4.9%, largely due to VYGR’s performance for the day.
About Voyager Therapeutics
Voyager Therapeutics (Nasdaq: VYGR) is leading the next generation of AAV gene therapy to unlock the potential of the modality to treat devastating diseases. Proprietary capsids born from the Company’s TRACER discovery platform are powering a rich early-stage pipeline of new and second-generation programs and may elevate the field to overcome the narrow therapeutic window associated with conventional gene therapy vectors across neurologic disorders and other therapeutic areas.